Accelerated Approval for RECCE® 327, page-47

It was introduced to US govt in March 2017 in the following bill whack is still progressing;
"S.771 - Improving Access To Affordable Prescription Drugs Act115th Congress (2017-2018)"
You can find that on congress . gov, it would be an automatic prize for the creation. If you have solve antibacterial resistance you won't be hard to find, it doesn't operate on a scholarship/research grant style.

There are other incentives that exist and ncbi has a great article (amongst others) "Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps", which details many existing prizes and many prizes in the pipelines;

"Multiple major reports recommend that a programme of market entry rewards is needed to adequately incentivise innovative antibiotic development.1, 7, 8, 47 At present, end prizes have only been used to reward development of rapid diagnostic tools for infectious diseases, the largest prize being the US NIH’s prize of $20 million.8 Proposed individual market entry rewards for novel antibiotics range from $1 to $2 billion per licensed antibiotic.47 Awarded antibiotics must meet a pre-specified target product profile and must be marketed according to sustainability and patient access standards. Another sensible recommendation is by Rex and Outterson who propose that market entry rewards could have a baseline prize that is supplemented by innovation bonuses for achieving certain clinical goals.50"


https://www.ohe.org/publications/incentives-new-drugs-tackle-anti-microbial-resistance is another great article including a downloadable publication on incentives


GLTAH/DYOR